hit counter
BeiGene, Ltd. (BGNE) Stock News Sentiment & Price - Sentifly
BGNE - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



BeiGene, Ltd. (BGNE)

Cayman Islands
Biotechnology
NASDAQ
BGNE Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
BGNE Latest news
Business Wire
Neutral
BeiGene and Nanolek Announce Approval in Russia for BRUKINSA® (Zanubrutinib) for Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma
2021-10-20 07:00

CAMBRIDGE, Mass. & BEIJING & MOSCOW--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene and Nanolek announce BRUKINSA® (zanubrutinib) approval in Russia for treatment of patients with relapsed or refractory mantle cell lymphoma.

Business Wire
Neutral
BeiGene Announces BRUKINSA® (Zanubrutinib) Approved for Treatment of Patients with Mantle Cell Lymphoma in Australia
2021-10-10 17:00

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene Announces BRUKINSA® (Zanubrutinib) Approved for Treatment of Patients with Mantle Cell Lymphoma in Australia

Business Wire
Neutral
BeiGene Announces BRUKINSA® (Zanubrutinib) Approved for Treatment of Patients with Mantle Cell Lymphoma
2021-10-10 17:00

SYDNEY & CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene Announces BRUKINSA® (Zanubrutinib) Approved for Treatment of Patients with Mantle Cell Lymphoma

Business Wire
Neutral
BeiGene Announces First Regulatory Approval in Australia for BRUKINSA® (Zanubrutinib) for Treatment of Patients with Waldenström's Macroglobulinemia
2021-10-07 16:06

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that BRUKINSA® (zanubrutinib) has been approved in Australia for the treatment of adult patients with Waldenström's macroglobulinemia (WM) who have received at least one prior therapy or in first line treatment for patients unsuita

Business Wire
Neutral
BeiGene Announces First Regulatory Approval in Australia for BRUKINSA® (Zanubrutinib) for Treatment of Patients with Waldenström's Macroglobulinemia
2021-10-07 16:05

SYDNEY & CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene Announces First Regulatory Approval in Australia for BRUKINSA® (Zanubrutinib) for Treatment of Patients with Waldenström's Macroglobulinemia

GuruFocus
Positive
2 Outperforming Biotech Stocks to Examine on Covid-19 Vaccine Updates
2021-09-21 12:13

With recent updates from Pfizer Inc. ( PFE , Financial) and BioNTech SE ( BNTX , Financial) regarding the effectiveness of their Covid-19 vaccine among children ages 5 to 11 and Johnson & Johnson's ( JNJ , Financial) booster shot announcement, consumers and investors alike are continuing to carefully watch the health care space.

Forbes
Positive
BeiGene Stock Rises 46% In A Month But Will The Rally Continue?
2021-09-21 08:00

The stock price of BeiGene, a biotechnology company focused on developing molecularly targeted and immuno-oncology drug candidates, has seen a rise of 46% over the last twenty-one trading days, while it is up 54% year-t0-date. The recent rise in the stock can be attributed to the U.S. FDA's.

Business Wire
Neutral
BeiGene Announces Inclusion in FTSE Russell Indices
2021-09-20 07:00

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene announced inclusion in several FTSE Russell indices.

Benzinga
Positive
Why BeiGene Shares Are Rising
2021-09-17 14:17

Beigene Ltd (NASDAQ: BGNE) shares are trading higher by 3.8% at $400 after the company announced it received a positive CHMP opinion for BRUKINSA for the treatment of adults with Waldenström's macroglobulinemia. "Bruton's tyrosine kinase (BTK) inhibitors have emerged as a promising treatment for WM, yet treatment discontinuation due to lack of response or side effects remains a concern," said Prof.

The Motley Fool
Positive
Why BeiGene's Shares Jumped on Friday
2021-09-17 13:17

The Chinese pharmaceutical company is racking up approvals for its lead oncology drug, Brukinsa.

Loading more news...